



/OIBE

## RAW SEQUENCE LISTING

DATE: 07/19/2002

PATENT APPLICATION: US/10/039,119A

TIME: 15:12:15

Input Set : A:\STEM1110-4.ST25.txt

Output Set: N:\CRF3\07192002\J039119A.raw

**ENTERED**

2 <110> APPLICANT: STEM CELL PHARMACEUTICALS, INC.  
 3 TWARDZIK, Daniel R.  
 4 PERNET, Andre  
 5 FELKER, Thomas S.  
 6 PASKELL, Stefan  
 8 <120> TITLE OF INVENTION: TGF-alpha POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF  
 USE THEREFOR  
 10 <130> FILE REFERENCE: STEM1110-4  
 12 <140> CURRENT APPLICATION NUMBER: US 10/039,119A  
 C--> 13 <141> CURRENT FILING DATE: 2002-07-02  
 15 <150> PRIOR APPLICATION NUMBER: US 09/641,587  
 16 <151> PRIOR FILING DATE: 2000-08-17  
 18 <150> PRIOR APPLICATION NUMBER: US 09/492,935  
 19 <151> PRIOR FILING DATE: 2000-01-17  
 21 <150> PRIOR APPLICATION NUMBER: US 09/378,567  
 22 <151> PRIOR FILING DATE: 1999-08-19  
 24 <160> NUMBER OF SEQ ID NOS: 7  
 26 <170> SOFTWARE: PatentIn version 3.1  
 28 <210> SEQ ID NO: 1  
 29 <211> LENGTH: 50  
 30 <212> TYPE: PRT  
 31 <213> ORGANISM: Homo sapiens  
 33 <400> SEQUENCE: 1  
 35 Val Val Ser His Phe Asn Asp Cys Pro Asp Ser His Thr Gln Phe Cys  
 36 1 5 10 15  
 39 Phe His Gly Thr Cys Arg Phe Leu Val Gln Glu Asp Lys Pro Ala Cys  
 40 20 25 30  
 43 Val Cys His Ser Gly Tyr Val Gly Ala Arg Cys Glu His Ala Asp Leu  
 44 35 40 45  
 47 Leu Ala  
 48 50  
 51 <210> SEQ ID NO: 2  
 52 <211> LENGTH: 50  
 53 <212> TYPE: PRT  
 54 <213> ORGANISM: Rattus norvegicus  
 56 <400> SEQUENCE: 2  
 58 Val Val Ser His Phe Asn Lys Cys Pro Asp Ser His Thr Gln Tyr Cys  
 59 1 5 10 15  
 62 Phe His Gly Thr Cys Arg Phe Leu Val Gln Glu Glu Lys Pro Ala Cys  
 63 20 25 30  
 66 Val Cys His Ser Gly Tyr Val Gly Val Arg Cys Glu His Ala Asp Leu  
 67 35 40 45  
 70 Asp Ala  
 71 50

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/039,119A

DATE: 07/19/2002

TIME: 15:12:15

Input Set : A:\STEM1110-4.ST25.txt

Output Set: N:\CRF3\07192002\J039119A.raw

74 <210> SEQ ID NO: 3  
 75 <211> LENGTH: 57  
 76 <212> TYPE: PRT  
 77 <213> ORGANISM: Artificial Sequence  
 79 <220> FEATURE:  
 80 <223> OTHER INFORMATION: A modified human TGF-alpha sequence  
 82 <400> SEQUENCE: 3  
 84 Ser Leu Ser Leu Pro Ala Met Val Val Ser His Phe Asn Asp Cys Pro  
 85 1 5 10 15  
 88 Asp Ser His Thr Gln Phe Cys Phe His Gly Thr Cys Arg Phe Leu Val  
 89 20 25 30  
 92 Gln Glu Asp Lys Pro Ala Cys Val Cys His Ser Gly Tyr Val Gly Ala  
 93 35 40 45  
 96 Arg Cys Glu His Ala Asp Leu Leu Ala  
 97 50 55

100 <210> SEQ ID NO: 4  
 101 <211> LENGTH: 11  
 102 <212> TYPE: PRT  
 103 <213> ORGANISM: Artificial Sequence  
 105 <220> FEATURE:  
 106 <223> OTHER INFORMATION: Modified human TGF alpha sequence fragment  
 108 <220> FEATURE:  
 109 <221> NAME/KEY: MISC\_FEATURE  
 110 <222> LOCATION: (1)..(10)  
 111 <223> OTHER INFORMATION: Xaa at residue 1, 5, 7 to 9 is independently V, G or A; Xaa

at

112 residue 6 is Y or F; and Xaa at residue 10 is R or K

114 <400> SEQUENCE: 4

W--> 116 Xaa Cys His Ser Xaa Xaa Xaa Xaa Xaa Cys  
 117 1 5 10

120 <210> SEQ ID NO: 5  
 121 <211> LENGTH: 7  
 122 <212> TYPE: PRT  
 123 <213> ORGANISM: Artificial Sequence  
 125 <220> FEATURE:  
 126 <223> OTHER INFORMATION: Modified human TGF alpha sequence fragment  
 128 <220> FEATURE:  
 129 <221> NAME/KEY: MISC\_FEATURE  
 130 <222> LOCATION: (1)..(7)  
 131 <223> OTHER INFORMATION: Xaa at residue 1 and 4 is E or D; Xaa at residue 3 and 7 is

V, G,

132 or A; Xaa at residue 5 is L or I; and Xaa at residue 6 is D or E

135 <400> SEQUENCE: 5

W--> 137 Xaa His Xaa Xaa Xaa Xaa Xaa  
 138 1 5

141 <210> SEQ ID NO: 6  
 142 <211> LENGTH: 18  
 143 <212> TYPE: PRT  
 144 <213> ORGANISM: Artificial Sequence  
 146 <220> FEATURE:  
 147 <223> OTHER INFORMATION: Modified human TGF alpha sequence fragment

## RAW SEQUENCE LISTING

DATE: 07/19/2002

PATENT APPLICATION: US/10/039,119A

TIME: 15:12:15

Input Set : A:\STEM1110-4.ST25.txt

Output Set: N:\CRF3\07192002\J039119A.raw

149 <220> FEATURE:  
 150 <221> NAME/KEY: MISC\_FEATURE  
 151 <222> LOCATION: (1)..(18)  
 152 <223> OTHER INFORMATION: Xaa at residue 1, 5, 7-9, 14, 18 is indep. V, G, or A; Xaa  
 at  
 153 residue 6 is Y or F; Xaa at residue 10 is R or K; Xaa at residue 12,  
 154 15 is indep. E or D; Xaa at residue 16 is L or I; Xaa at residue  
 155 17 is D or E  
 157 <400> SEQUENCE: 6  
 W--> 159 Xaa Cys His Ser Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa His Xaa Xaa Xaa  
 160 1 5 10 15  
 W--> 163 Xaa Xaa  
 167 <210> SEQ ID NO: 7  
 168 <211> LENGTH: 7  
 169 <212> TYPE: PRT  
 170 <213> ORGANISM: Artificial Sequence  
 172 <220> FEATURE:  
 173 <223> OTHER INFORMATION: Modified human TGF alpha sequence fragment  
 175 <220> FEATURE:  
 176 <221> NAME/KEY: MISC\_FEATURE  
 177 <222> LOCATION: (1)..(7)  
 178 <223> OTHER INFORMATION: Xaa at residue 1 and 2 is indep. V, G, and A; Xaa at residue  
 7 is  
 179 K or R  
 181 <400> SEQUENCE: 7  
 W--> 183 Xaa Xaa Ser His Phe Gln Xaa  
 184 1 5

RAW SEQUENCE LISTING ERROR SUMMARY  
PATENT APPLICATION: US/10/039,119A

DATE: 07/19/2002  
TIME: 15:12:16

Input Set : A:\STEM1110-4.ST25.txt  
Output Set: N:\CRF3\07192002\J039119A.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:4; Xaa Pos. 1,5,6,7,8,9,10

Seq#:5; Xaa Pos. 1,3,4,5,6,7

Seq#:6; Xaa Pos. 1,5,6,7,8,9,10,12,14,15,16,17,18

Seq#:7; Xaa Pos. 1,2,7

Invalid Line Length:

The rules require that a line not exceed 72 characters in length. This includes spaces.

Seq#:1; Line(s) 8